Children with acute myelogenous leukemia (AML) who achieve remission may receive consolidation therapy with either allogeneic bone marrow transplantation (allo-BMT) or consolidation chemotherapy (CCT). While survival outcomes are similar, allo-BMT is associated with unique long-term complications, raising concerns about quality of life. This study examined mood-related health-related quality of life (HRQL) in long-term survivors of pediatric AML using the Profile of Mood States (POMS). Among 124 survivors, no significant differences in mood disturbance were found between treatment groups. Overall mood scores were comparable to the general population, suggesting that allo-BMT does not confer additional long-term mood impairment compared to chemotherapy.
